Literature DB >> 19829292

Chronic creatine supplementation alters depression-like behavior in rodents in a sex-dependent manner.

Patricia J Allen1, Kristen E D'Anci, Robin B Kanarek, Perry F Renshaw.   

Abstract

Impairments in bioenergetic function, cellular resiliency, and structural plasticity are associated with the pathogenesis of mood disorders. Preliminary evidence suggests that creatine, an ergogenic compound known to promote cell survival and influence the production and usage of energy in the brain, can improve mood in treatment-resistant patients. This study examined the effects of chronic creatine supplementation using the forced swim test (FST), an animal model selectively sensitive to antidepressants with clinical efficacy in human beings. Thirty male (experiment 1) and 36 female (experiment 2) Sprague-Dawley rats were maintained on either chow alone or chow blended with either 2% w/w creatine monohydrate or 4% w/w creatine monohydrate for 5 weeks before the FST. Open field exploration and wire suspension tests were used to rule out general psychostimulant effects. Male rats maintained on 4% creatine displayed increased immobility in the FST as compared with controls with no differences by diet in the open field test, whereas female rats maintained on 4% creatine displayed decreased immobility in the FST and less anxiety in the open field test compared with controls. Open field and wire suspension tests confirmed that creatine supplementation did not produce differences in physical ability or motor function. The present findings suggest that creatine supplementation alters depression-like behavior in the FST in a sex-dependent manner in rodents, with female rats displaying an antidepressant-like response. Although the mechanisms of action are unclear, sex differences in creatine metabolism and the hormonal milieu are likely involved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19829292      PMCID: PMC2794979          DOI: 10.1038/npp.2009.160

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  102 in total

Review 1.  Non-genomic actions of estrogens and their interaction with genomic actions in the brain.

Authors:  Nandini Vasudevan; Donald W Pfaff
Journal:  Front Neuroendocrinol       Date:  2007-10-01       Impact factor: 8.606

Review 2.  Stress, depression, and neuroplasticity: a convergence of mechanisms.

Authors:  Christopher Pittenger; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2007-09-12       Impact factor: 7.853

3.  Social isolation increases number of newly proliferated cells in hippocampus in female flinders sensitive line rats.

Authors:  Astrid Bjørnebekk; Aleksander A Mathé; Susanne H M Gruber; Stefan Brené
Journal:  Hippocampus       Date:  2007       Impact factor: 3.899

4.  Creatine monohydrate in resistant depression: a preliminary study.

Authors:  Suzana Roitman; Tamar Green; Yamima Osher; Nathan Karni; Joseph Levine
Journal:  Bipolar Disord       Date:  2007-11       Impact factor: 6.744

5.  Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder.

Authors:  Dan V Iosifescu; Nicolas R Bolo; Andrew A Nierenberg; J Eric Jensen; Maurizio Fava; Perry F Renshaw
Journal:  Biol Psychiatry       Date:  2008-01-22       Impact factor: 13.382

Review 6.  Mitochondrial involvement in psychiatric disorders.

Authors:  Ling Shao; Maureen V Martin; Stanley J Watson; Alan Schatzberg; Huda Akil; Richard M Myers; Edward G Jones; William E Bunney; Marquis P Vawter
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

7.  The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors.

Authors:  Rui Wang; Ying Xu; Hong-Li Wu; Ying-Bo Li; Yu-Hua Li; Jia-Bin Guo; Xue-Jun Li
Journal:  Eur J Pharmacol       Date:  2007-09-19       Impact factor: 4.432

Review 8.  Functions and effects of creatine in the central nervous system.

Authors:  Robert H Andres; Angélique D Ducray; Uwe Schlattner; Theo Wallimann; Hans Rudolf Widmer
Journal:  Brain Res Bull       Date:  2008-03-24       Impact factor: 4.077

9.  Social isolation in prairie voles induces behaviors relevant to negative affect: toward the development of a rodent model focused on co-occurring depression and anxiety.

Authors:  Angela J Grippo; Kevin D Wu; Iman Hassan; C Sue Carter
Journal:  Depress Anxiety       Date:  2008       Impact factor: 6.505

10.  Lateralized caudate metabolic abnormalities in adolescent major depressive disorder: a proton MR spectroscopy study.

Authors:  Vilma Gabbay; David A Hess; Songtao Liu; James S Babb; Rachel G Klein; Oded Gonen
Journal:  Am J Psychiatry       Date:  2007-12       Impact factor: 18.112

View more
  33 in total

1.  Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.

Authors:  Douglas G Kondo; Young-Hoon Sung; Tracy L Hellem; Kristen K Fiedler; Xianfeng Shi; Eun-Kee Jeong; Perry F Renshaw
Journal:  J Affect Disord       Date:  2011-08-09       Impact factor: 4.839

2.  Incidence of major depressive episode correlates with elevation of substate region of residence.

Authors:  Kristen DelMastro; Tracy Hellem; Namkug Kim; Douglas Kondo; Young-Hoon Sung; Perry F Renshaw
Journal:  J Affect Disord       Date:  2010-11-11       Impact factor: 4.839

3.  Chronic high-dose creatine has opposing effects on depression-related gene expression and behavior in intact and sex hormone-treated gonadectomized male and female rats.

Authors:  Patricia J Allen; Joseph F DeBold; Maribel Rios; Robin B Kanarek
Journal:  Pharmacol Biochem Behav       Date:  2015-01-03       Impact factor: 3.533

4.  Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats.

Authors:  Patricia J Allen; Kristen E D'Anci; Robin B Kanarek; Perry F Renshaw
Journal:  Pharmacol Biochem Behav       Date:  2012-03-10       Impact factor: 3.533

5.  Involvement of PI3K/Akt Signaling Pathway and Its Downstream Intracellular Targets in the Antidepressant-Like Effect of Creatine.

Authors:  Mauricio P Cunha; Josiane Budni; Fabiana K Ludka; Francis L Pazini; Julia Macedo Rosa; Ágatha Oliveira; Mark W Lopes; Carla I Tasca; Rodrigo B Leal; Ana Lúcia S Rodrigues
Journal:  Mol Neurobiol       Date:  2015-05-06       Impact factor: 5.590

Review 6.  Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?

Authors:  Patricia J Allen
Journal:  Neurosci Biobehav Rev       Date:  2012-03-24       Impact factor: 8.989

Review 7.  Factors influencing behavior in the forced swim test.

Authors:  Olena V Bogdanova; Shami Kanekar; Kristen E D'Anci; Perry F Renshaw
Journal:  Physiol Behav       Date:  2013-05-14

8.  CD300f immunoreceptor is associated with major depressive disorder and decreased microglial metabolic fitness.

Authors:  Natalia Lago; Fernanda N Kaufmann; María Luciana Negro-Demontel; Daniela Alí-Ruiz; Gabriele Ghisleni; Natalia Rego; Andrea Arcas-García; Nathalia Vitureira; Karen Jansen; Luciano M Souza; Ricardo A Silva; Diogo R Lara; Bruno Pannunzio; Juan Andrés Abin-Carriquiry; Jesús Amo-Aparicio; Celia Martin-Otal; Hugo Naya; Dorian B McGavern; Joan Sayós; Rubèn López-Vales; Manuella P Kaster; Hugo Peluffo
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-09       Impact factor: 11.205

9.  A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.

Authors:  In Kyoon Lyoo; Sujung Yoon; Tae-Suk Kim; Jaeuk Hwang; Jieun E Kim; Wangyoun Won; Sujin Bae; Perry F Renshaw
Journal:  Am J Psychiatry       Date:  2012-09       Impact factor: 18.112

10.  Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study.

Authors:  Tracy L Hellem; Young-Hoon Sung; Xian-Feng Shi; Marjorie A Pett; Gwen Latendresse; Jubel Morgan; Rebekah S Huber; Danielle Kuykendall; Kelly J Lundberg; Perry F Renshaw
Journal:  J Dual Diagn       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.